摘要
T辅助细胞(Th)是适应性免疫系统,提供了一个有效的和特异性宿主的保护手段。Th17细胞是Th细胞亚群,由炎性细胞因子白细胞介素(IL)- 17A(IL-17A)和IL-17F,绑定到受体IL-17RA和IL-17RC亚基组成的复合体。Th17细胞抵抗外细胞和真菌感染,但有伴随的自身免疫性疾病。在许多自身免疫性疾病,异常免疫反应涉及到免疫系统中的几个部分,包括抗体、T细胞和B细胞。有针对性的生物疗法是有吸引力的,因为它们可以防止患者的不必要的副作用。这是不断完善的证据:Th17细胞针对在肾小球免疫性疾病中,血管性或化学性损伤对肾小管的损伤,无论是通过一个特定的攻击肾小球基底膜或全身炎症性疾病的一部分,对肾脏是非常重要的。靶向治疗IL-17A、IL-12p40和IL-17RA的临床试验正在研究或正在使用于临床实践中对其他治疗IL-17介导的疾病,如银屑病。本文探讨IL-17A和Th17细胞可能在免疫性肾脏疾病致病的目前证据,包括抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,狼疮性肾炎,以及急性肾损伤。它将讨论生物制剂对IL-17A、IL-12p40和IL-17RA在治疗这些疾病的部位。
关键词: 急性肾损伤,抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,白细胞介素17,白细胞介素12p40,系统性红斑狼疮,Th17细胞。
Current Medicinal Chemistry
Title:Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Volume: 22 Issue: 38
Author(s): Joanna R. Ghali, Stephen R. Holdsworth and A. Richard Kitching
Affiliation:
关键词: 急性肾损伤,抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,白细胞介素17,白细胞介素12p40,系统性红斑狼疮,Th17细胞。
摘要: T helper (Th) cells belong to the adaptive immune system and provide an effective and antigen-specific means of host protection. Th17 cells are a subset of Th cells, characterized by the production of the inflammatory cytokines interleukin (IL)-17A (IL-17A) and IL-17F, which bind to a receptor complex comprised of IL-17RA and IL-17RC subunits. Th17 cells combat extracellular and fungal infections, but have been implicated in autoimmune diseases. In many autoimmune conditions, the dysregulated immune response involves several parts of the immune system, including autoantibodies, B and T cells. Targeted biological therapies are appealing, as they may prevent unwanted side effects in patients. There is evolving evidence that Th17 cells are important in the kidney, mediating injury in response to vascular or chemical insults to the renal tubules, and in autoimmune diseases of the glomerulus, either through a specific attack on the glomerular basement membrane or as part of a generalized systemic inflammatory disease. Therapies targeting IL-17A, IL-12p40 and IL-17RA are being explored in clinical trials or are being utilized in clinical practice for the treatment of other IL-17 mediated diseases, such as psoriasis. This review explores the current evidence that IL-17A and Th17 cells may be pathogenic in immune kidney disease, including anti-glomerular basement membrane disease, antineutrophil cytoplasmic antibody associated vasculitis and lupus nephritis, as well as in acute kidney injury. It will discuss the place that biological agents against IL-17A, IL-12p40 and IL-17RA may have in the treatment of these conditions.
Export Options
About this article
Cite this article as:
Joanna R. Ghali, Stephen R. Holdsworth and A. Richard Kitching , Targeting IL-17 and IL-23 in Immune Mediated Renal Disease, Current Medicinal Chemistry 2015; 22 (38) . https://dx.doi.org/10.2174/0929867322666151030163022
DOI https://dx.doi.org/10.2174/0929867322666151030163022 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ATP Binding Cassette Transporter A1 (ABCA1) Associated Proteins:Potential Drug Targets in the Metabolic Syndrome and Atherosclerotic Disease?
Current Pharmaceutical Biotechnology FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued) Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin
Current Signal Transduction Therapy Giant Cell Arteritis (GCA): Pathogenesis, Clinical Aspects and Treatment Approaches
Current Rheumatology Reviews The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) GCPII Variants, Paralogs and Orthologs
Current Medicinal Chemistry Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?
Current Rheumatology Reviews Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Heerfordt-Waldenström Syndrome, A Rare Presentation of Sarcoidosis in a Patient with Old Ocular Toxoplasmosis
Infectious Disorders - Drug Targets